Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC
AG Pallis, KN Syrigos - Lung cancer, 2013 - Elsevier
Improvements in our understanding of the molecular biology of cancer have shifted
management of lung cancer toward molecular-guided, individualized treatment …
management of lung cancer toward molecular-guided, individualized treatment …
[HTML][HTML] Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature
Erlotinib and gefitinib are among the most widely researched, used and available
molecularly targeted therapies for treatment of advanced non-small cell lung cancer …
molecularly targeted therapies for treatment of advanced non-small cell lung cancer …
PRDM14 promotes the migration of human non-small cell lung cancer through extracellular matrix degradation in vitro
HX Bi, HB Shi, T Zhang, G Cui - Chinese medical journal, 2015 - journals.lww.com
Background: As a novel molecular markerof non-small cell lung cancer (NSCLC), PRDI-BF1
and RIZ homology domain containing protein 14 (PRDM14) is over-expressed in NSCLC …
and RIZ homology domain containing protein 14 (PRDM14) is over-expressed in NSCLC …
[HTML][HTML] Re-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer
Z Song, X Yu, C He, B Zhang… - Journal of Thoracic …, 2013 - ncbi.nlm.nih.gov
Objective Few treatment options are available for advanced non-small cell lung cancer
(NSCLC) patients who have failed of gefitinib or erlotinib treatment in second/third-line …
(NSCLC) patients who have failed of gefitinib or erlotinib treatment in second/third-line …
Economic burden of advanced lung cancer patients treated by gefitinib alone and combined with chemotherapy in two regions of China
K Yang, S Hua, W Wei, C Yang, X Zhu… - Journal of Medical …, 2023 - Taylor & Francis
Aim To assess the economic burden of different chemotherapies for lung cancer patients
and influencing factors in China. Materials and methods The economic burden of lung …
and influencing factors in China. Materials and methods The economic burden of lung …
[HTML][HTML] Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
GH Xia, Y Zeng, Y Fang, SR Yu, L Wang… - Cancer Biology & …, 2014 - ncbi.nlm.nih.gov
Objective Non-small cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR)-activating mutations have higher response rate and more prolonged …
receptor (EGFR)-activating mutations have higher response rate and more prolonged …
Subsequent treatment choices for patients with acquired resistance to EGFR-TKIs in non-small cell lung cancer: restore after a drug holiday or switch to another EGFR …
T Song, W Yu, SX Wu - Asian Pacific Journal of Cancer Prevention, 2014 - koreascience.kr
The outcomes of first-generation EGFR-TKIs (Gefitnib and Erlotinib) have shown great
advantages over traditional treatment strategies in patients with non-small cell lung cancer …
advantages over traditional treatment strategies in patients with non-small cell lung cancer …
[HTML][HTML] Erlotinib and gefitinib treatments of the lung cancer in an elderly patient result in gastrointestinal bleeding
H Bai, Q Liu, M Shi, J Zhang - Pakistan journal of medical sciences, 2013 - ncbi.nlm.nih.gov
Lung cancer is currently one of the leading causes of the cancer-related deaths in the world.
Erlotinib and Gefitinib are inhibitors of human epidermal growth factor receptor-1 and the …
Erlotinib and Gefitinib are inhibitors of human epidermal growth factor receptor-1 and the …
[PDF][PDF] Treatment and prognosis after progression in long-term responders to EGFR-tyrosine kinase inhibitor in advanced non-small cell lung cancer
Z Song, Y Zhang - Archives of Medical Science, 2016 - termedia.pl
Results: In total, 521 patients were administered EGFR-TKI. Of these, 298 patients received
EGFR-TKI with progression-free survival less than 6 months (group A), and the other 223 …
EGFR-TKI with progression-free survival less than 6 months (group A), and the other 223 …